DHEA ( DrugBank: DHEA )
3 diseases
| ID | Disease name (Link within this page) | Number of trials |
|---|---|---|
| 49 | Systemic lupus erythematosus | 1 |
| 86 | Pulmonary arterial hypertension | 1 |
| 96 | Crohn disease | 1 |
49. Systemic lupus erythematosus
Clinical trials : 946 / Drugs : 722 - (DrugBank : 186) / Drug target genes : 117 - Drug target pathways : 199
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | NCT00189124 (ClinicalTrials.gov) | September 2003 | 13/9/2005 | Dehydroepiandrosterone (DHEA) in Systemic Lupus Erythematosus (SLE) for Coronary Artery Disease (CAD) Prevention | Does DHEA Improve Endothelial Dysfunction and Other Cardiovascular Risk Factors in Premenopausal Women With Systemic Lupus? | Systemic Lupus Erythematosus | Drug: Dehydroepiandrosterone (DHEA) | University of Michigan | Arthritis Foundation | Completed | 18 Years | N/A | Female | 13 | Phase 2/Phase 3 | United States |
86. Pulmonary arterial hypertension
Clinical trials : 1,181 / Drugs : 701 - (DrugBank : 126) / Drug target genes : 105 - Drug target pathways : 192
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | NCT03648385 (ClinicalTrials.gov) | January 9, 2019 | 10/8/2018 | Effects of DHEA in Pulmonary Hypertension | Effects of DHEA in Pulmonary Hypertension | Pulmonary Arterial Hypertension | Drug: DHEA tablet;Other: Placebo | Rhode Island Hospital | NULL | Recruiting | 18 Years | N/A | All | 24 | Phase 2 | United States |
96. Crohn disease
Clinical trials : 2,400 / Drugs : 1,391 - (DrugBank : 267) / Drug target genes : 170 - Drug target pathways : 215
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | NCT00106314 (ClinicalTrials.gov) | January 2005 | 22/3/2005 | An Efficacy and Safety Evaluation of Inflabloc Cap in the Treatment of Patients With Crohn's Disease | A Randomized, Double-Blind, Multi-Center, Dose Response, Efficacy and Safety Evaluation of Inflabloc Cap in the Treatment of Patients With Moderately Active Crohn's Disease | Crohn's Disease | Drug: Dehydroepiandrosterone [DHEA] | Inflabloc Pharmaceuticals | NULL | Completed | 18 Years | N/A | Both | 75 | Phase 2 | United States;Canada |